{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:23:02Z","timestamp":1786465382810,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Logistics support Ministry special subject"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"DOI":"10.1007\/s15010-026-02897-6","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T14:58:31Z","timestamp":1786460311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy and safety of omadacycline plus \u03b2-lactam versus moxifloxacin plus \u03b2-lactam for the treatment of severe community-acquired pneumonia: study protocol of a multicenter, prospective, randomized controlled non-inferiority trial"],"prefix":"10.1007","author":[{"given":"Xin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyang","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunbiao","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenkai","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixia","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"issue":"10258","key":"2897_CR1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204\u201322.","journal-title":"Lancet"},{"issue":"1","key":"2897_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41572-021-00259-0","volume":"7","author":"A Torres","year":"2021","unstructured":"Torres A, Cilloniz C, Niederman MS, et al. Pneumonia Nat Rev Dis Primers. 2021;7(1):25. https:\/\/doi.org\/10.1038\/s41572-021-00259-0","journal-title":"Pneumonia Nat Rev Dis Primers"},{"issue":"1","key":"2897_CR3","doi-asserted-by":"publisher","first-page":"e0191721","DOI":"10.1371\/journal.pone.0191721","volume":"13","author":"M Ferrer","year":"2018","unstructured":"Ferrer M, Travierso C, Cilloniz C, et al. Severe community-acquired pneumonia: characteristics and prognostic factors in ventilated and nonventilated patients. PLoS ONE. 2018;13(1):e0191721.","journal-title":"PLoS ONE"},{"issue":"3","key":"2897_CR4","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.chest.2020.03.051","volume":"158","author":"R Cavallazzi","year":"2020","unstructured":"Cavallazzi R, Furmanek S, Arnold FW, et al. The burden of community-acquired pneumonia requiring admission to ICU in the United States. Chest. 2020;158(3):1008\u201316.","journal-title":"Chest"},{"issue":"6","key":"2897_CR5","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00134-023-07033-8","volume":"49","author":"I Martin-Loeches","year":"2023","unstructured":"Martin-Loeches I, Torres A, Nagavci B, et al. ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med. 2023;49(6):615\u201332.","journal-title":"Intensive Care Med"},{"issue":"7","key":"2897_CR6","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45\u201367.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"2897_CR7","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.3201\/eid3112.250872","volume":"31","author":"Z Fatima","year":"2025","unstructured":"Fatima Z, Jayaratne P, Arrabi A, et al. Macrolide resistance and P1 cytadhesin genotyping of Mycoplasma pneumoniae during outbreak, Canada, 2024\u20132025. Emerg Infect Dis. 2025;31(12):2316\u20139.","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"2897_CR8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1128\/CMR.00114-16","volume":"30","author":"KB Waites","year":"2017","unstructured":"Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP. Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev. 2017;30(3):747\u2013809.","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"2897_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/phar.1761","volume":"36","author":"MR Bidell","year":"2016","unstructured":"Bidell MR, Lodise TP. Fluoroquinolone-associated tendinopathy: does levofloxacin pose the greatest risk? Pharmacotherapy. 2016;36(6):679\u201393.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"2897_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40264-018-0751-2","volume":"42","author":"E Gorelik","year":"2019","unstructured":"Gorelik E, Masarwa R, Perlman A, Rotshild V, Muszkat M, Matok I. Fluoroquinolones and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis. Drug Saf. 2019;42(4):529\u201338.","journal-title":"Drug Saf"},{"issue":"4","key":"2897_CR11","doi-asserted-by":"publisher","first-page":"e0221321","DOI":"10.1128\/aac.02213-21","volume":"67","author":"SM Bhavnani","year":"2023","unstructured":"Bhavnani SM, Hammel JP, Lakota EA, et al. Pharmacokinetic-pharmacodynamic target attainment analyses evaluating omadacycline dosing regimens for the treatment of patients with community-acquired bacterial pneumonia arising from Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob Agents Chemother. 2023;67(4):e0221321.","journal-title":"Antimicrob Agents Chemother"},{"issue":"14","key":"2897_CR12","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2217\/fmb-2016-0100","volume":"11","author":"S Villano","year":"2016","unstructured":"Villano S, Steenbergen J, Loh E. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. Future Microbiol. 2016;11(14):1421\u201334.","journal-title":"Future Microbiol"},{"issue":"5","key":"2897_CR13","doi-asserted-by":"publisher","first-page":"e02488","DOI":"10.1128\/AAC.02488-19","volume":"64","author":"MA Pfaller","year":"2020","unstructured":"Pfaller MA, Huband MD, Shortridge D, Flamm RK. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018. Antimicrob Agents Chemother. 2020;64(5):e02488\u201319.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2897_CR14","doi-asserted-by":"publisher","first-page":"e02411","DOI":"10.1128\/AAC.02411-16","volume":"61","author":"MA Pfaller","year":"2017","unstructured":"Pfaller MA, Rhomberg PR, Huband MD, Flamm RK. Activities of omadacycline and comparator agents against Staphylococcus aureus isolates from a surveillance program conducted in North America and Europe. Antimicrob Agents Chemother. 2017;61(3):e02411\u201316.","journal-title":"Antimicrob Agents Chemother"},{"key":"2897_CR15","unstructured":"US Food and Drug Administration. NUZYRA (omadacycline). 2018. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209816\\_209817lbl.pdf"},{"issue":"6","key":"2897_CR16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa1800201","volume":"380","author":"R Stets","year":"2019","unstructured":"Stets R, Popescu M, Gonong JR, et al. Omadacycline for Community-Acquired Bacterial Pneumonia. N Engl J Med. 2019;380(6):517\u201327.","journal-title":"N Engl J Med"},{"key":"2897_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ijid.2021.01.032","volume":"104","author":"A Torres","year":"2021","unstructured":"Torres A, Garrity-Ryan L, Kirsch C, et al. Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia. Int J Infect Dis. 2021;104:501\u20139.","journal-title":"Int J Infect Dis"},{"key":"2897_CR18","unstructured":"Chen YJ, Gao SY, Fu J et al. The efficacy and safety of omadacycline in treating acute bacterial infections: a meta-analysis of randomized controlled trials. Expert Opin Drug Saf 2025 Feb 16:1\u201311."},{"key":"2897_CR19","doi-asserted-by":"publisher","first-page":"e081660","DOI":"10.1136\/bmj-2024-081660","volume":"389","author":"A Hr\u00f3bjartsson","year":"2025","unstructured":"Hr\u00f3bjartsson A, Boutron I, Hopewell S, et al. SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials. BMJ. 2025;389:e081660.","journal-title":"BMJ"},{"key":"2897_CR20","doi-asserted-by":"publisher","first-page":"e081123","DOI":"10.1136\/bmj-2024-081123","volume":"389","author":"S Hopewell","year":"2025","unstructured":"Hopewell S, Chan AW, Collins GS, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025;389:e081123.","journal-title":"BMJ"},{"key":"2897_CR21","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","volume":"163","author":"MS Niederman","year":"2001","unstructured":"Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730\u201354.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2897_CR22","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/j.chest.2020.05.598","volume":"158","author":"JA Ramirez","year":"2020","unstructured":"Ramirez JA, Musher DM, Evans SE, et al. Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies. Chest. 2020;158(5):1896\u2013911.","journal-title":"Chest"},{"issue":"5","key":"2897_CR23","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1016\/S2666-5247(23)00031-9","volume":"4","author":"YN Liu","year":"2023","unstructured":"Liu YN, Zhang YF, Xu Q, et al. Infection and co-infection patterns of community-acquired pneumonia in patients of different ages in China from 2009 to 2020: a national surveillance study. Lancet Microbe. 2023;4(5):e330\u20139.","journal-title":"Lancet Microbe"},{"issue":"1","key":"2897_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12879-023-08166-3","volume":"23","author":"LL Zhang","year":"2023","unstructured":"Zhang LL, Xiao Y, Zhang GL, et al. Identification of priority pathogens for aetiological diagnosis in adults with community-acquired pneumonia in China: a multicentre prospective study. BMC Infect Dis. 2023;23(1):231.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"2897_CR25","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.cmi.2017.09.014","volume":"24","author":"XM Nie","year":"2018","unstructured":"Nie XM, Li YS, Yang ZW, et al. Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals. Clin Microbiol Infect. 2018;24(6):658. e1-658.e6.","journal-title":"Clin Microbiol Infect"},{"key":"2897_CR26","first-page":"100968","volume":"42","author":"GH Fan","year":"2023","unstructured":"Fan GH, Zhou YC, Zhou F, et al. The mortality and years of life lost for community-acquired pneumonia before and during COVID-19 pandemic in China. Lancet Reg Health West Pac. 2023;42:100968.","journal-title":"Lancet Reg Health West Pac"},{"issue":"6","key":"2897_CR27","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.cmi.2016.03.015","volume":"22","author":"AF Simonetti","year":"2016","unstructured":"Simonetti AF, Garcia-Vidal C, Viasus D, et al. Declining mortality among hospitalized patients with community-acquired pneumonia. Clin Microbiol Infect. 2016;22(6):567. e1-567.e7.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"2897_CR28","doi-asserted-by":"publisher","first-page":"7044","DOI":"10.1128\/AAC.01536-15","volume":"59","author":"L Honeyman","year":"2015","unstructured":"Honeyman L, Ismail M, Nelson ML, et al. Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline. Antimicrob Agents Chemother. 2015;59(11):7044\u201353.","journal-title":"Antimicrob Agents Chemother"},{"key":"2897_CR29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jgar.2021.09.011","volume":"27","author":"MA Pfaller","year":"2021","unstructured":"Pfaller MA, Huband MD, Shortridge D, et al. Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY antimicrobial surveillance program, 2019. J Glob Antimicrob Resist. 2021;27:337\u201351.","journal-title":"J Glob Antimicrob Resist"},{"issue":"2","key":"2897_CR30","doi-asserted-by":"publisher","first-page":"e0108724","DOI":"10.1128\/aac.01087-24","volume":"69","author":"TM File Jr","year":"2025","unstructured":"File TM Jr, Ramirez JA, Wilde AM. New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on M. abscessus). Antimicrob Agents Chemother. 2025;69(2):e0108724.","journal-title":"Antimicrob Agents Chemother"},{"key":"2897_CR31","unstructured":"Paratek Pharmaceuticals. Paratek pharmaceuticals announces positive top-line efficacy and safety data from post-marketing study of NUZYRA (omadacycline) for patients with moderate to severe community-acquired bacterial pneumonia. 2024. Available from: https:\/\/www.globenewswire.com\/news-release\/2024\/ 07\/18\/2915177\/0\/en\/Paratek-Pharmaceuticals-Announces-Positive-Top-line-Efficacy-and-Safety-Data-from-Post-Marketing-Study-of-NUZYRA-omadacycline-for-Patients-with-Moderate-to-Severe-Community-Acquire.html"},{"key":"2897_CR32","doi-asserted-by":"publisher","first-page":"1181633","DOI":"10.3389\/fcimb.2023.1181633","volume":"13","author":"JL Li","year":"2023","unstructured":"Li JL, Liu LS, Zhang H, et al. Severe problem of macrolides resistance to common pathogens in China. Front Cell Infect Microbiol. 2023;13:1181633.","journal-title":"Front Cell Infect Microbiol"},{"key":"2897_CR33","doi-asserted-by":"publisher","first-page":"102589","DOI":"10.1016\/j.eclinm.2024.102589","volume":"71","author":"FQ Cai","year":"2024","unstructured":"Cai FQ, Li JL, Liang WJ, et al. Effectiveness and safety of tetracyclines and quinolones in people with Mycoplasma pneumonia: a systematic review and network meta-analysis. EClinicalMedicine. 2024;71:102589.","journal-title":"EClinicalMedicine"},{"issue":"6","key":"2897_CR34","first-page":"627","volume":"24","author":"Y Guo","year":"2024","unstructured":"Guo Y, Hu F, Zhu D, et al. Surveillance of bacterial resistance in China (CHINET) in 2023. Chin J Infect Chemother. 2024;24(6):627\u201337.","journal-title":"Chin J Infect Chemother"},{"issue":"1","key":"2897_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.14715\/cmb\/2022.69.1.13","volume":"69","author":"HY Sun","year":"2023","unstructured":"Sun HY, Chai XL, Xu GX, et al. The formation and drug resistance mechanism of biofilm for Streptococcus pneumoniae infection in severe respiratory patients. Cell Mol Biol (Noisy-le-grand). 2023;69(1):75\u201380.","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"2897_CR36","doi-asserted-by":"publisher","first-page":"838790","DOI":"10.3389\/fmicb.2022.838790","volume":"13","author":"ML Zhou","year":"2022","unstructured":"Zhou ML, Wang LL, Wang ZR, et al. Molecular characterization of penicillin-binding Protein2x, 2b and 1a of Streptococcus pneumoniae causing invasive pneumococcal diseases in China: a multicenter study. Front Microbiol. 2022;13:838790.","journal-title":"Front Microbiol"},{"issue":"4","key":"2897_CR37","doi-asserted-by":"publisher","first-page":"115179","DOI":"10.1016\/j.diagmicrobio.2020.115179","volume":"98","author":"C Pickens","year":"2020","unstructured":"Pickens C, Wunderink RG, Qi C, et al. A multiplex polymerase chain reaction assay for antibiotic stewardship in suspected pneumonia. Diagn Microbiol Infect Dis. 2020;98(4):115179.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"2897_CR38","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S2213-2600(17)30120-0","volume":"5","author":"NJ Brendish","year":"2017","unstructured":"Brendish NJ, Malachira AK, Armstrong L, et al. Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial. Lancet Respir Med. 2017;5(5):401\u201311.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2897_CR39","first-page":"CD011825","volume":"1","author":"MP Hansen","year":"2019","unstructured":"Hansen MP, Scott AM, McCullough A, et al. Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane Database Syst Rev. 2019;1(1):CD011825.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10 Pt 2","key":"2897_CR40","first-page":"S253","volume":"21","author":"DN Fish","year":"2001","unstructured":"Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy. 2001;21(10 Pt 2):S253\u201372.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"2897_CR41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/sim.1425","volume":"22","author":"RB D\u2019Agostino","year":"2003","unstructured":"D\u2019Agostino RB, Sr, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues \u2013 the encounters of academic consultants in statistics. Stat Med. 2003;22(2):169\u201386.","journal-title":"Stat Med"},{"key":"2897_CR42","unstructured":"Food and Drug Administration. Guidance for Industry: Non-Inferiority Clinical Trials to Establish Effectiveness. U.S. Department of Health and Human Services. 2016."},{"key":"2897_CR43","volume-title":"National Guidelines for Antimicrobial Therapy","author":"National Expert Committee on Rational Drug Use, National Health and Family Planning Commission, editor","year":"2017","unstructured":"National Expert Committee on Rational Drug Use, National Health and Family Planning Commission, editor. National Guidelines for Antimicrobial Therapy. 2nd ed. Beijing: People\u2019s Medical Publishing House; 2017.","edition":"2"},{"issue":"5","key":"2897_CR44","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/cid\/civ927","volume":"62","author":"GH Talbot","year":"2016","unstructured":"Talbot GH, Powers JH, Hoffmann SC, Biomarkers Consortium of the Foundation for the National Institutes of Health CABP-ABSSSI and HABP-VABP Project Teams. Developing Outcomes Assessments as Endpoints for Registrational Clinical Trials of Antibacterial Drugs: 2015 Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin Infect Dis. 2016;62(5):603\u20137.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2897_CR45","doi-asserted-by":"publisher","first-page":"dlae078","DOI":"10.1093\/jacamr\/dlae078","volume":"6","author":"R Valenzuela","year":"2024","unstructured":"Valenzuela R, Ochoa M, Mu\u00f1oz MF, et al. Ceftaroline fosamil treatment patterns and outcomes in adults with community-acquired pneumonia: a real-world multinational, retrospective study. JAC-Antimicrobial Resist. 2024;6(3):dlae078.","journal-title":"JAC-Antimicrobial Resist"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02897-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02897-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02897-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T14:58:34Z","timestamp":1786460314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02897-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":45,"alternative-id":["2897"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02897-6","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"4 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving humans are approved by the medical ethics committee of the Chinese PLA General Hospital (Registration No. KY-2025-8-167-1) or the responsible ethics committee of each respective study center and conducted in accordance with the revised Declaration of Helsinki. Written informed consent is obtained from the patients or a legal representative.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In all cases, enrollment and consent are obtained exclusively through face-to-face discussions conducted by a qualified researcher (attending investigator or trained research coordinator) who is independent of the patient\u2019s direct clinical care team, ensuring no conflict of interest.","order":4,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Recruiting has be started in September 2025. Patient recruitment is estimated to be completed around December 2026.","order":5,"name":"Ethics","label":"Trial status","group":{"name":"EthicsHeading","label":"Declarations"}}]}}